The MUC1-Targeted Silica Nanocarrier (MPPM):
Scientists from the Agharkar Research Institute (ARI) in Pune have developed an innovative gene-silencing nanomedicine that drives effective tumor inhibition in breast cancer.The nanomedicine is named the MUC1-Targeted Silica Nanocarrier, also structurally designated as MPPM. It is an engineered, biodegradable mesoporous silica nanohybrid platform designed to operate as a vehicle for targeted gene therapy. The system uses customizable surface chemistry to encapsulate and transport genetic material safely into the body.This platform was developed by a team of Indian scientists from the Nanobioscience Group at the Agharkar Research Institute (ARI), Pune.The aim of MPPM is to achieve precise, localized gene silencing within malignant breast cancer cells while minimizing systemic toxicity.By shutting down specific survival pathways that allow tumors to resist conventional treatments, the platform seeks to offer a safer and more effective alternative to traditional chemotherapy.
